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Background: Diffuse alveolar hemorrhage (DAH) is a clinical syndrome with typical symptoms 
dyspnea and hemoptysis. DAH is a complication of specific diseases, in some cases with acute 
catastrophic hemoptysis, while other patients present low grade alveolar bleeding with a need 
of chronic transfusion as in pulmonary hemosiderosis.
Methods: Current literature in the PubMed database and other sources was reviewed in order 
to evaluate the current treatment recommendations, efficacy of this treatment, and finally the 
risk of complications after off-label use of rFVIIa in respect to DAH.
Objectives: (i) To elucidate the clinical aspects of alveolar hemorrhage, (ii) to develop 
a simple diagnostic algorithm in order to separate DAH from other important pulmonary 
diseases with similar clinical picture and comparably high mortality. Such an algorithm has 
important therapeutic consequences because these diseases: acute lung injury (ALI), acute 
respiratory distress syndrome (ARDS) and bronchiolitis obliterans organizing pneumonia 
(BOOP) have different therapies, (iii) to evaluate and discuss whether local pulmonary 
administration may improve outcome and reduce mortality in DAH, and (iv) to suggest a 
treatment schedule.
Results: Hitherto the diagnosis and treatment of DAH has been based on anecdotal reports. 
The treatment has relied on different unspecific treatment modalities based on a mixture of 
treatment of the underlying disease and treatment without evidence targeted to stop the alveo-
lar bleeding. However, recently a number of publications have advocated the use of intrapul-
monary rFVIIa. Even in severe bleeding DAH has been shown to respond promptly without 
thromboembolic complication when FVIIa was administered locally via the air side, because 
the FVIIa does not penetrate the alveolo-capillary membrane to the blood-side. The incidence 
of  DAH (in the US and Europe is 100,000–150,000, and 50,000 patients annually are at risk 
of developing DAH following hematopoietic stem cell transplant (HSCT) and autoimmune 
diseases. Finally 50,000–100,000 patients may be falsely categorized as having acute respira-
tory distress syndrome/acute lung injury (ARDS/ALI) because DAH and ARDS cannot be 
separated clinically. A new treatment paradigm of DAH is proposed as no other intervention has 
been able to ensure pulmonary hemostasis in DAH. The diagnosis of DAH is simple, a series of 
broncho-alveolar washes which become increasingly bloody. This test should be performed in all 
patients with pulmonary opacities in order to separate ARDS/ALI from DAH. FVIIa adminis-
trated via pulmonary route is “drug of choice”, because it stops bleeding in the life-threatening 
syndrome DAH. Hemostasis is obtained after only one to two small doses of FVIIa (50 µg/kg 
body weight per dose) and after hemostasis the oxygen transport quickly improves.
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Conclusion: Intrapulmonary administration of rFVIIa is recommended as the treatment of choice for DAH and blast lung injury (BLI) because 
the treatment has been shown to be successful and uncomplicated in spite of the fact that only a small series of DAH has been documented.
Keywords: coagulation factor FVIIa, diffuse alveolar hemorrhage, hemosiderosis, blast lung injury, local pulmonary treatment, biologics, 
bronchoalveolar lavage, diagnosis, algorithm,  new treatment recommendation
of the granulocyte macrophage colony stimulating factor 
(GM-CSF) receptor, documenting that it was necessary to 
inhale the drug in order to reach the receptor on the air side 
(Figure 1). Intravenous administration of GM-CSF had no 
effect on the alveolar macrophages whereas the inhaled drug 
increased the number of macrophages with no interference 
with systemic monocytes.1
In the normal airspace the hemostatic balance is skewed 
toward anticoagulation due to increased expression of plas-
minogen activator and low expression of tissue factor (TF). 
As soon as the lungs are exposed to an inflammatory process, 
the anticoagulatory state will swiftly be turned into a proco-
agulatory state – a primitive host defense reaction in order 
to stop the invasiveness of bacteria and to hinder bacterial 
multiplication and dissemination.2
On the air side a whole host of receptors are placed. The 
complex cross talk between the dynamic receptor expres-
sion and the overall effect is hard to predict. It is known that 
pulmonary receptors ensure pulmonary host defense, ie, 
the TF and GM-CSF-receptors, both placed on the airside 
isolated from the blood side.3,4 The different biologics must 
fulfill certain qualities in order to be able to penetrate the 
biological membranes. First of all the molecular size must 
be small, most likely smaller than 15–20 kDa, like insulin 
with a molecular size of 8 kDa. Secondly, the drug must be 
lipophilic in order to cross the alveolo-capillary membrane to 
reach the peripheral airways. However, no newly developed 
therapeutic recombinant drug fulfills the low size criteria 
Table 1 DAH – the key points
Clinical picture 
• DAH is characterized clinically by alveolar bleeding, from mild with chronic transfusion need to the catastrophic alveolar bleeding with hemoptysis.
The DAH presents with three subsets 
• Macroscopic bleeding – mortality of .70%. 
•   Chronic microscopic alveolar bleeding, falling hematocrit, sputum filled with hemosiderin laden macrophages. The mortality is low, however, the life 
expectancy is reduced due to pulmonary fibrosis.
• Blast lung injury after a major blast. The subset seemingly has a “window of opportunity” of 3 hours. 
The diagnosis of DAH 
•   Bronchoalveolar lavage with aliquot with successive lavage fluid bloodier macro/microscopically than the previous one. In this way DAH may be 
separated from ARDS/ALI and BOOP.
Treatment of DAH 
•   Alveolar bleeding may be treated successfully provided the DAH syndrome is treated locally intrapulmonarily, by lavage or inhalation.
• Prophylaxis of DAH is only based on the specific optimization of the multiple underlying diseases and conditions.
Abbreviations:  ALI,  acute  lung  injury;  ARDS,  acute  respiratory  distress  syndrome;  BOOP,  bronchiolitis  obliterans  organizing  pneumonia;  DAH,  diffuse  alveolar 
hemorrhage.
Introduction
There is a general lack of understanding of the gap between, 
on the one hand, the “air side”, where the effective drug-
related receptors are located and, on the other hand, the 
vascular compartment. When administered intravenously 
biological drugs like FVIIa do not reach the receptors in the 
alveoli, because they do not pass the alveolo-capillary mem-
brane. “Biologics” refer to biologically manufactured drugs, 
similar to endogenously key signaling proteins, like FVIIa.
Traditionally, biologics are administered intravenously 
with the hope that a sufficient concentration of the drug 
reaches the specific receptors. This requires a high systemic 
concentration of the drug and is associated with a higher 
risk of adverse systemic effects than local application at the 
target site. 
The syndrome of diffuse bleeding DAH
The diffuse alveolar hemorrhage (DAH) syndrome has a 
number of clinical characteristics similar to a number of 
well-pulmonary documented conditions like acute respira-
tory distress syndrome (ARDS), acute lung insufficiency 
(ALI), and bronchiolitis obliterans organizing pneumonia 
(BOOP) (Table 1).
Diffuse alveolar hemorrhage related  
to pulmonary receptors in perspective
For many years it has been known that even the air side of 
the lung has receptors. Rose et al made a functional study 
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in as much as all the wild type proteins are all hydrophilic 
FVIIa and GM-CSF.
Pathophysiology of DAH
DAH is characterized by damage to the alveolar-capillary 
basement membrane allowing red blood cells to enter the 
alveolar spaces. Most frequently DAH is a symptom of 
pulmonary capillaritis as seen in autoimmune diseases or 
after hematopoietic stem cell transplant (HSCT). DAH may 
also occur as a result of diffuse alveolar damage in acute 
respiratory distress syndrome/acute lung injury (ARDS/ALI). 
Further the damage may be the result of physicochemical 
factors like blast lung injury (BLI), toxic drug effects (eg, 
cytotoxic drugs, crack cocaine inhalation), and radiation 
therapy (Figure 2).
Epidemiology of DAH
In hematological stem cell transplantation (HSCT) recipi-
ents, DAH is an infrequent cause of death both in early and 
late phases after transplantation.5,6 DAH after HSCT is a 
devastating complication that carries an overall mortality of 
16%–70%.7,8 As a result of life-threatening multiple organ 
dysfunctions, 15%– 40% of HSCT recipients receive 
intensive care unit support, the majority of whom require 
mechanical ventilation.9–11 The mortality rate of HSCT 
recipients receiving invasive ventilation used to exceed 
90%.10,12 Although more recent studies have shown improve-
ment in outcome, the mortality rate of HSCT recipients 
receiving mechanical ventilation is still high.10,13–15 It is esti-
mated that 50,000 HSCT procedures took place in 2007 in 
the USA, and 80,000 worldwide, and that 25%–40% of 
HSCT recipients are admitted to the medical intensive care 
unit (ICU) for the management of pulmonary complications 
to HSCT.7,11,16,17
A considerable number of patients will also develop 
DAH due to other causes than HSCT, eg, infections, bron-
choscopy, autoimmune diseases, HIV (Kaposi’s sarcoma), 
and transplantations, ie, DAH has been reported in 75% of 
patients with Kaposi’s sarcoma,18 in 66% of patients with 
SLE,19 5%–10% of patients with Goodpasture syndrome.20 
Fatal DAH has been reported in approximately 10%–41% 
of lung autopsies of HSCT patients that succumbed to 
HSCT related complications.6,21 Further, DAH is reported to 
develop in 40% of patients admitted to the ICU for respira-
tory failure (ARDS/ALI). The annual incidence of ARDS/
ALI in the USA and EU admitted to ICU is over 500,000 
patients.
The syndrome of DAH
The multiple causes of DAH are shown in Table 222 together 
with the treatment of the underlying cause of DAH and symp-
tomatic treatment of the ongoing alveolar bleeding. Formerly, 
the management strategy was limited to the optimization 
of each of the specific diseases and underlying disorders 
Figure 1 Local pulmonary administration of FVIIa into the airways ensures that 
the drug reaches its alveolar receptor TF. However, most importantly, taking into 
account the separation between the two compartments the “air side” and the 
“systemic side”, there will not be systemic adverse effects in as much as the alveolo-
capillary membrane does not allow the transmembranous passage of FVIIa, when 
inhaled. FVIIa does not pass through the alveolo-capillary membrane either from the 
(A) alveolus or (B) the blood side. 
Abbreviation: TF, tissue factor.
Acute DAH
macroscopic bleeding
Blast lung injury
Chronic DAH
microscopic bleeding
DAH
Figure 2 The DAH syndrome is the common denominator of multiple diseases and 
conditions. DAH is the general alveolar response to multiple underlying diseases 
and conditions. The syndrome DAH manifests itself in three subsets: the acute 
catastrophic DAH, the chronic DAH and finally as the instant blast lung injury. 
The acute DAH has been treated with local intrapulmonary FVIIa administration. 
The  two  other  subsets  could  potentially  also  be  treated  from  the  air  side,  an 
intervention which remains to be shown. 
Abbreviation: DAH, diffuse alveolar hemorrhage.
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as a prophylactic measure toward prevention of DAH 
syndrome. Most of such prophylactic interventions have 
been treatment with steroids, anti-infective measures, eg, 
anti-cytomegalovirus pneumonia therapy, plasmapheresis, 
platelet transfusion, and coagulation factors. These inter-
ventions are alone focused on prophylaxis of the stereotype 
syndrome alveolar bleeding.
The diagnosis of DAH
The algorithmic scheme is depicted in Figure 3, based on the 
fact that the signs and symptoms are a common denominator 
of DAH, ARDS and BOOP: acute pulmonary insufficiency 
with reduced O2 transport capacity and confluent opacities on 
chest film. It is imperative to distinguish between the specific 
diagnoses of these conditions, and in as much as they have 
a very high mortality, it is of utmost importance to diagnose 
correctly because the specific therapies are different. The key 
to the diagnosis, as it appears in Figure 3, is the finding of (i) a 
macroscopically progressively hemorrhagic aliquot in a series 
of bronchoalveolar lavage fluid (BALF) findings that denote a 
severe DAH syndrome, or (ii) measurements of an increased 
hemoglobin concentration in the BALF corresponding to a slow 
bleeding (pulmonary hemosiderosis), or (iii) absence of bloody 
return in the BALF excluding the DAH diagnosis. The remaining 
two conditions are separated by a simple flow-cytometry (FC) 
on the BALF, where the BOOP is characterized by abundant 
inflammatory cells, and the ARDS diagnosis is based on a BALF 
without inflammatory cells and without bloody return.
DAH in childhood and adolescence
DAH occurs in any age group secondary to the same underly-
ing diseases and conditions. However, the major   difference 
Table 2 Overview of diseasesyndromes and other causes leading to DAH and the classical options of treatment
Syndromes Clinical presentations Classic options of treatment22
Pulmonary capillaritis or  
autoimmune diseases
Systemic lupus erythematosus 
Goodpasture’s syndrome 
Antiphospholipid syndrome 
wegner’s granulomatosis 
Scleroderma rheumatoid arthritis 
Henoch Schönlein purpura 
Acute lung allograft rejection 
Bone marrow transplantation
Immunosuppressants 
  • Steroids 
  • Methotrexate 
  • Retuximab 
Removal of autoantibodies 
  • Plasmapheresis 
Procoagulation 
  • Plasma 
  • Tranexamic acid 
  • Platelet transfusion 
  • Coagulation factors
Diffuse alveolar damage Radiation therapy 
Cytotoxic drugs 
ARDS
Traumatic alveolocapillary membrane Blast lung injury
Mixed Multiple myeloma 
Subacute bacterial endocarditis 
Negative pressure pulmonary edema 
Mitral stenosis 
Idiopathic pulmonary hemosiderosis 
Coagulation disorders 
Pulmonary veno-occlusive disease
Drug induced alveolocapillary membrane warfarin 
Isocyanates 
Nitrofurantoin 
Propylthiouracil 
Clopidogrel 
Fibrinolytics 
Aspirin 
Amiodarone 
Phenytoin
 
+ Discontinuation of treatment
Infections Bacteria 
Pseudomonas aeruginosa 
Leptospirosis 
Mycoses 
Aspergillus spp. 
Virus infections 
CMV and herpes pneumonitis
 
+ Broad spectrum antibiotics and antiviral therapy
Abbreviations: ARDS, acute respiratory distress syndrome; CMV, cytomegalovirus; DAH, diffuse alveolar hemorrhage.
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is that the DAH syndrome is characterized by microscopic 
alveolar bleeding with chronic transfusion need. Hemoptysis 
is seldom. The chronic erythrocyte intraalveolar bleeding often 
surpasses the metabolic clearance of iron originating from 
the erythrocyte metabolism of the alveolar macrophage. This 
leads to an alveolar iron overload. These patients don’t have 
a considerable acute mortality, but a severely reduced long 
term life-expectancy due to pulmonary fibrosis secondary to 
accumulated iron in the alveolar space.
Pulmonary hemosiderosis
The idiopathic pulmonary hemosiderosis syndrome (IPH) is 
a DAH condition, however, without known underlying cause, 
ie, the incidence and prevalence of IPH is unknown. There are 
approximately 500 cases reported in the literature, primarily 
in children (80%). The etiology of IPH is not clear, in spite of 
many theories. Clinically, the signs and symptoms of IPH are 
identical to other microalveolar bleedings like the acquired 
pulmonary hemosiderosis secondary to known underly-
ing diseases, ie, exacerbations concomitantly with cough, 
dyspnea to fulminant respiratory failure. The chronic state 
is accompanied with variable degrees of iron deficiency ane-
mia, present in most patients. Spirometry shows a restrictive 
pattern due to pulmonary fibrosis in the chronic   condition. 
Lung biopsies from both IPH and secondary pulmonary 
hemosiderosis patients often show severe thickening of the 
alveolar wall and hemosiderin-loaded alveolar macrophages 
that also appear in sputum.
The blast lung injury – a dynamic process 
with a “window of opportunity”
A blast lung injury (BLI) is based on the disruption of the 
alveolo-capillary membrane after an explosion, with a sig-
nificant pressure wave entailing diffuse alveolar bleeding 
(Table 3).23
Based on the pathophysiology, BLI can be characterized 
into distinct phases of a dynamic process (Table 4).24–26 This 
leads to (i) diffuse bleeding and (ii) hemolysis which quantita-
tively surpasses the clearance rate of free iron (Fe++) from the 
alveoli unless the diffuse alveolar bleeding is stopped early.
It seems that there is a “window of opportunity” of 
3 hours in which the BLI is reversible (Table 5). If the 
Bilateral diffuse infiltraates
Reduced oxygen transport
Macroscopic
BALF
Bronchoalveolar lavage
fluid (BALF)
Yes
Bloody
BALF
No
FC
Acute DAH Chronic DAH
Microscopic
BALF
No cells
ALI/ARDS
+++ cells
BOOP
Figure 3 The diagnostic algorithm for DAH, BOOP and ARDS. The clinical signs and symptoms of DAH, ALI/ARDS and BOOP are identical, ie, chest film with confluent 
opacities, acute pulmonary insufficiency with reduced O2 transport capacity. It is imperative to separate between the specific diagnoses of each of these conditions, in as 
much as they all have a high mortality; it is of utmost importance to diagnose correctly because the specific therapies are different. The simple algorithmic separation is based 
on progressively hemorrhagic aliquot of a series of BALF’s either macroscopically which denote a severe DAH syndrome or measurements of an increased hemoglobin 
concentration in the BALF which corresponds to a slow bleeding DAH like in IPH. Provided there is no bloody return at the BALF the DAH diagnosis is excluded. The 
remaining two conditions are separated by a simple flow-cytometry on the BALF, where the BOOP is characterized by abundant inflammatory cells, and the ARDS diagnosis 
is based on a BALF without inflammatory cells or bloody return. 
Abbreviations: ALI, acute lung injury; ARDS, acute respiratory distress syndrome; BALF, bronchoalveolar lavage fluid; BOOP, bronchiolitis obliterans organizing pneumonia; 
DAH, diffuse alveolar hemorrhage, FC, flow cytometry; IPH, idiopathic pulmonary hemosiderosis.
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hemorrhage is not brought to a halt, the severity of the 
pulmonary   dysfunction increases over the next 4 days into 
irreversible BLI and fatal pulmonary failure. The BLI occurs 
when soldiers in the battlefield or the civilian population are 
exposed to bomb attacks. Inhalation of FVIIa is an obvious 
measure to treat the BLI within the window of opportunity, 
which could be an indication for use of FVIIa in respect to 
the military and homeland use, because BLI affects soldiers 
in the battlefield as well as victims of terror attacks.
BLI – signs, symptoms and outcome
BLI secondary to high explosives causes life-threatening 
dysfunction of the lungs of soldiers exposed to a blast. 
The incidence of BLI is not known, but may be as high as 
1000–5000 persons annually.
There are to date no reports of the prevalence of DAH 
in blast lungs because it is a military secret. BLI may occur 
in the absence of any external signs of trauma, as seen in a 
series of 517 blast casualties, where approximately 20% were 
immediately fatal.23
Treatment of DAH
Hitherto the separation between symptomatic intervention 
towards life threatening DAH and the optimization of the 
underlying disease has not been properly addressed – a fact 
which has caused confusion concerning the discussion of the 
best way to administer FVIIa as an intravenous infusion or 
as an airway deposition, ie, as a BALF administration or as 
an inhalation (Figure 4).
A common denominator for these studies is that the trials 
generally have only a very small number of patients included, 
thereby evading proper statistical evaluation.27,28 In 2006 a 
study was published with a sufficient number of patients to 
reach a statistical significant effect of local FVIIa. Before 
this time treatment was a mixed intervention of questionable 
effect with steroids, anti-infective measures, plasmapheresis, 
platelet transfusion, and intravenous infusion of FVlla and 
other procoagulation factors in spite of the fact that DAH 
bleeding is not due to factor deficiency.29,30
As late as in 2011 it is still suggested that treatment of 
DAH should be based “on the underlying cause of   hemorrhage, 
Table 3 Overview of BLI – a dynamic condition23
Definition and pathogenesis The traumatic DAH secondary to primary blast BLI is a special form of DAH but triggered 
  (i)   By a “blast wave” secondary to a high explosive detonation. The expanding high pressure 
wave induces destructive interaction between the pressure wave, the lung tissue and 
pulmonary vasculature leading to a disruption of tissues at the air-blood interface.
  (ii) wth a subsequent resonance inducing hemolysis of the intra-alveolar space.
Natural course of BLI From the early phase with bleeding over mild hemolysis to the end stage with irreversible 
lung injury based on insufficient iron clearance. Reversible provided therapy is initiated 
within the first 3 hours – “the window of opportunity.”
Treatment window The blast injury secondary to high-explosives is life-threatening and the window of 
opportunity is narrow which means that time for treatment is of essence. 
The time window for intervention is only 3 hours. Preemptive* inhalation of FVIIa can 
eliminate the risk of mortality or permanent lung dysfunction secondary to BLI.
Battlefield and homeland security Inhalation of FVIIa implies that BLI casualties may be evacuated from the war zone by 
helicopter and ensure a safe home transport to acquire final treatment in an allied hospital.
Note: *Preemptive is predefined prophylaxis based on (i) a major blast exposure within the 3 hours open window, most preferably 30 minutes after the exposure. 
Abbreviations: BLI, blast lung injury; DAH, diffuse alveolar hemorrhage.
Table 4 After a major blast the three phases have their own distinct problems24–26
Timing Pathophysiology of the post blast pulmonary injury phases
Phase 1 
0–3 hours
Hemorrhagic phase 
  •   Transmigration of inflammatory leucocytes, inflammatory stress and destruction of endothelial 
integrity
 •  window of opportunity
Phase 2 
4–12 hours
Alveolar inflammation 
  • Extravasation of blood with transmigration of inflammatory leucocytes into the hemorrhagic lesions 
  •   Subsequent biodegradation of hemoglobin with deposition of iron in alveoli accompanied by 
degranulation of neutrophils
Phase 3 
13–56 hours
Pulmonary destruction 
  • Increased transferrin – bound Fe (3+) and non-transferrin complexes of Fe (3+) 
  •   Subsequently disruption of alveolar capillary network and necrotic changes in the pulmonary 
epithelial cells
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with corticosteroids as a mainstay of therapy in most cases”,22 
despite of the first series of a systematic treatment of DAH 
with local intrapulmonary FVIIa in 2006.31 This study docu-
mented an effect of administering a small intrabronchial dose 
of FVIIa. The effect of intrabronchial lavage with a simple 
saline solution of FVIIa demonstrated (i) that no patient suc-
cumbed after the treatment due to alveolar bleeding, (ii) a 
significantly improved oxygen gas exchange (P = 0.024), and 
(iii) a balanced hemostasis (P = 0.031). These findings were 
subsequently reproduced by three later publications from three 
independent centers using the identical treatment protocol, 
however, each study had only a few patients included.32–34 
None of the four studies adverse effects (AE) were reported, 
probably because there was no detectable transmembraneous 
FVIIa passage from the air side into the blood as evaluated by 
the prothrombin time. The pathophysiological understanding 
of the mechanism of action, the marked effect, and the fact 
that no patients died or were encountering adverse effects as 
a consequence of the local treatment with FVIIa was most 
likely the reason for being granted the orphan drug (OD) 
designation in both Europe (European Medicines Agency 
[EMEA]), Canary Wharf, London and secondly in the USA 
(Food and Drug Administration [FDA], Virginia, USA) in 
spite of the theoretical risk of intra-alveolar thrombotic com-
Table 5 Diffuse alveolar hemorrhage – the treatment paradigm
DAH subtype Clinical signs and symptoms Route of administration Effective dose
Macroscopic alveolar  
bleeding
Hemoptysis and severely reduced oxygen transport  
capacity and confluent opacities on chest films
Bronchoalveolar lavage with 25 mL  
saline via each main bronchusa
75 µg/kg FVIIa31–34
Microscopic alveolar  
bleeding or hemosiderosis
Chronic transfusion requirement and hemosiderin  
laden macrophages in expectorate
Inhaled FVIIab 75 µg/kg FVIIa31
Blast lung injury Initial dyspnea after the blast 
Increasing symptoms and eventually leading to  
hemoptysis or microscopic DAH 
window of opportunity of 3 hours
No information 
Animal proof of concept 
at DSTL 
Most likely the intervention would be  
inhalation of FVIIa, at least as a  
prehospital treatment
–
Notes: aThe total effective dose is dissolved in 50 mL; bUsing a micropump nebulizer interference with the two active sites of FVIIa is avoided. This treatment option was 
effectively administered in one patient who presented with recurrent bleeding after extubation; no further published experience exists. Note that the treatment regime is 
based on a limited number of patients.
Abbreviation: DSTL, British Defence Science and Technology Laboratory.
Acute DAH Chronic DAH
Outcome
Common therapy
local FVlla
DAH syndrome
Capillaritis
Causes of DAH
Autoimmune
diseases
HSTC Infections Drug induced
DAH
BLI
Specific therapy
Figure 4 It is essential to separate cause and the effect of DAH. It is important to separate the treatment of multiple underlying causes of DAH from the common 
complicating denominator DAH syndrome, because the latter is simply treated with local pulmonary FVIIa. 
Abbreviations: BLI, blast lung injury; DAH, diffuse alveolar hemorrhage; HSTC, hematopoietic stem cell transplant.
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plications, when treating DAH with FVIIa as a pulmonary 
deposition.22
However, the systemic administration of FVIIa for off-
label use for the treatment of uncontrollable life-threatening 
hemorrhage has been increasing since the introduction 
of FVIIa (NovoSeven®, Novo Nordisk A/S, Bagsværd, 
Denmark),35 but concomitantly a concern for potential 
thromboembolic complications has equally been increas-
ing, especially after the publication of several meta-analyses 
recommending caution due to ongoing reports of fatal 
complications.36,37
A suggestion for the treatment of the three conditions, 
DAH, pulmonary hemosiderosis and blast lung injury, is 
shown in Table 531–34 based on published documentation.
Patients suffering from chronic DAH as IPH, often 
children, are at present generally placed on high-dose ste-
roids, and then weaned to the lowest dose that keeps them 
from having exacerbations. The use of chronic high dose ste-
roids is problematic because the treatment induces multiple 
adverse effects both in children but also in the adolescent. 
The 5-year mortality rate in pediatric patients ranges from 
24% to 60%.38 Since no treatment is known at present to be 
effective, clinical trials with inhaled FVIIa are warranted. It 
is suggested that the end point could be a fall in numbers of 
hemosiderin-loaded macrophages in sputum combined with 
reduced transfusion need. Since FVIIa has a very high degree 
of efficacy in DAH and is without adverse effects, inhaled 
FVIIa in a small low daily dose will most likely serve as a 
prophylactic measure. Such a treatment scheme could make 
invasive procedures like single-lung transplantation super-
fluous as this treatment has shown no lasting effect because 
IPH recurred.38
However, to date no information on treatment of pul-
monary hemosiderosis and BLI has been published. In as 
much as pulmonary hemosiderosis and BLI share the same 
pathophysiological background alveolar bleeding, treatment 
suggested in Table 5 is an extrapolation from the published 
effective dose in DAH.
Every time the clinician encounters a condition where 
no documentation exists it should be considered whether the 
disease is worse than the treatment. In the case of using air 
side treatment of FVIIa in microalveolar bleeding, inhalation 
by a simple inhalation device seems to be the treatment of 
choice, ensuring swift deposition of FVIIa into the alveolar 
space, without the need for invasive procedures such as 
  bronchoscopy. Using a micropump nebulizer ensures that 
there will not be any interference with the active site of the 
FVIIa molecule. The only documented case of inhalation of 
FVIIa by a micropump where the DAH has been treated with 
  success was a patient with Wegener’s granulomatosis.31 The 
patient had been extubated a few hours earlier after a bout of 
hemoptysis and had presented with recurrence of the DAH 
through bloody tinged expectorate. Instead of reintubation 
she was treated with an FVIIa dose of 50 µg/kg BWT inhaled 
via a jet nebulizer. After 5 minutes the patient spontaneous 
exclaimed that the dyspnea had defervesced, and there were 
no further episodes of DAH.
Discussion
Biologics are relatively new approaches to treat hitherto untreat-
able diseases like the DAH syndrome. The immediate and 
positive effect of local FVIIa administered from the air side is 
due to the fact that the combined FVIIa and its receptor tissue 
factor (TF) will bring about a balanced hemostasis, ie, with both 
durable hemostasis for a remarkably small dose of FVIIa, and 
an improvement in oxygen transport capacity. These facts also 
explain the lack of systemic adverse effects (Figure 5).
DAH is a syndrome, not a disease, with three subsets. It 
is easily conceived that the acute macroscopic hemorrhage 
has a very high mortality .75%. The microscopic DAH 
subset has on the contrary a small acute mortality; however, 
with a severely reduced life expectancy. Lastly the DAH 
subset associated with blast injuries has anecdotally been 
FVlla–TF
FVlla
Tissue factor (TF)
2
1
Figure 5 Rationale for local pulmonary treatment of DAH with FVIIa. Intravenous 
rFVIIa does not reach the alveoli (1) in contrast to the airway route (2) where 
a direct access to the receptor TF is obtained. The TF-FVIIa complex activates 
coagulation  factor  IX  and  X.  Finally  the  activated  TF-FVIIa  complex  induces  a 
perfect “balanced” hemostasis ie, sufficient fibrin deposition without interference 
with the oxygen transport. The TFPI are constitutively expressed in the airspace in 
inflammatory conditions, secondary to alveolar inflammation. The TFPI is usually of 
less importance as compared to the procoagulatory factors. However, this might be 
the explanation for the balanced hemostasis. 
Abbreviations: DAH, diffuse alveolar hemorrhage; TF, tissue factor; TFPI, tissue 
factor inhibitors.
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s  uccessfully treated with inhaled FVIIa (pers comm; Danish 
Medical Center in Helmand province, Afghanistan and Lars 
Heslet, 2009).
The clinical picture, “white lungs” on chest film and 
severely reduced oxygen transport capacity, is a common 
denominator of the high mortality pulmonary diseases DAH, 
ARDS and BOOP. Diagnostically they may be separated by a 
simple algorithm: when an aliquot series of BAL fluid washes 
shows increasingly bloody return, irrespective of whether it 
is frons macro- or microscopic bleeding.
Therapy of the DAH syndrome seems to be simple 
because DAH is the common denominator of multiple 
underlying diseases and conditions. It is most important to 
separate the treatment of the alveolar bleeding from the opti-
mization of underlying disease like plasmaferesis, steroids, 
and antibiotics. Administration of FVIIa into the airways via 
local administration is suggested as an adjuvant therapy to 
treatment of the underlying disease (Figure 5). Taking into 
consideration the adverse effects of high-dose steroids often 
used in children with DAH or IPH and further the risk of 
acquiring irreversible pulmonary fibrosis due to insufficient 
iron clearance, a trial with inhaled FVIIa seems to be far less 
risky in spite of such an intervention.34
Conclusions
1.  The documented therapy from four independent centers 
of instillation of FVIIa or inhalation of the drug into the 
airways has demonstrated a sustained and immediate 
hemostatic effect in DAH, however, still only in a small 
number of patients.
2.  There is an obvious indication for this treatment in 
patients with the syndrome DAH and with BLI, being 
the first line intervention to treat the catastrophic high 
mortality of DAH. This treatment is also safe because 
the drug does not penetrate from ‘air’ to ‘blood’.
3.  Lastly, patients with confluent opacities on chest film 
and reduced oxygenation capacity like DAH, ARDS and 
BOOP, may according to a simple algorithm BALF wash 
test be categorized into distinctive groups and treated 
accordingly. It has been estimated that ARDS is likely 
to be over-diagnosed in 20%, an important issue because 
the treatments are different.
4.  Larger, however, not necessarily placebo-controlled stud-
ies are warranted, taking into account the high mortality 
when utilizing the above mentioned treatment recom-
mendations and based on the simple diagnostic algorithm 
to systematically separate the DAH syndrome from the 
conditions ARDS/ALI and BOOP.
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